CTRE Stock Analysis: CareTrust REIT | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 9.301m USD | 12M Return: 20.9% | US14174T1079 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 84.1M
EPS Trend: 98.8%
Qual. Beats: 0
Rev. Trend: 94.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CareTrust REIT, Inc. (NYSE: CTRE) is a self-administered, publicly traded real estate investment trust focused on the ownership, acquisition, financing, development, and leasing of skilled nursing facilities (SNFs), senior housing communities, and other healthcare-related properties. The company leases its properties to independent operators under a triple-net lease structure, which is common among healthcare REITs and shifts most property-level operating costs to tenants.
As of December 31, 2025, CareTrusts portfolio consisted of 407 SNFs, senior housing communities, and other properties comprising approximately 37,628 operational beds and units across 32 U.S. states and the United Kingdom. The highest concentration of properties by rental income was located in California, the U.K., Texas, and Tennessee.
In addition to its owned property portfolio, CareTrust held other real estate-related investments, including preferred equity investments, real estate secured loans, mezzanine loans, and a financing receivable. The company was established and incorporated on October 29, 2013, and is headquartered in Dana Point, California. Like most REITs, CareTrust is generally required to distribute the majority of its taxable income to shareholders in the form of dividends.
- SNF acquisition pipeline fuels portfolio expansion and FFO growth
- Interest rate volatility pressures cap rates and borrowing costs
- California and UK tenant concentration raises operator default risk
| Net Income: 355.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.81 > 1.0 |
| NWC/Revenue: 19.16% < 20% (prev 102.9%; Δ -83.74% < -1%) |
| CFO/TA 0.08 > 3% & CFO 447.0m > Net Income 355.4m |
| Net Debt (1.16b) to EBITDA (528.1m): 2.19 < 3 |
| Current Ratio: 1.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (234.2m) vs 12m ago 21.46% < -2% |
| Gross Margin: 77.91% > 18% (prev 94.92%; Δ -17.00% > 0.5%) |
| Asset Turnover: 10.27% > 50% (prev 5.95%; Δ 4.32% > 0%) |
| Interest Coverage Ratio: 8.19 > 6 (EBIT TTM 414.3m / Interest Expense TTM 50.6m) |
| A: 0.02 (Total Current Assets 625.1m - Total Current Liabilities 520.9m) / Total Assets 5.93b |
| B: -0.08 (Retained Earnings -503.2m / Total Assets 5.93b) |
| C: 0.08 (EBIT TTM 414.3m / Avg Total Assets 5.29b) |
| D: 3.17 (Book Value of Equity 4.49b / Total Liabilities 1.42b) |
| Altman-Z'' = 3.70 = AA |
As of September 02, 2026, the stock is trading at USD 39.93 with a total of 2,057,515 shares traded. Over the past week, the price has changed by +0.08%, over one month by -3.13%, over three months by +2.49% and over the past year by +20.94%.
Current recommended Stop Loss: 38.70 (which is 3.1% or 1.5 ATR below the current price).
CareTrust REIT has received a consensus analysts rating of 4.22. Therefore, it is recommended to buy CTRE.
- StrongBuy: 6
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 45.4 | 13.6% |
P/E Trailing = 24.6
P/E Forward = 21.322
P/S = 16.2757
P/B = 2.1013
P/EG = 1.26
Revenue TTM = 543.4m USD
EBIT TTM = 414.3m USD
EBITDA TTM = 528.1m USD
Long Term Debt = 895.1m USD (from longTermDebt, last quarter)
Short Term Debt = 310.0m USD (from shortTermDebt, last quarter)
Debt = 1.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.16b USD (calculated: Debt 1.21b - CCE 49.3m)
Enterprise Value = 10.5b USD (9.30b + Debt 1.21b - CCE 49.3m)
Interest Coverage Ratio = 8.19 (Ebit TTM 414.3m / Interest Expense TTM 50.6m)
EV/FCF = 24.24x (Enterprise Value 10.5b / FCF TTM 431.4m)
FCF Yield = 4.13% (FCF TTM 431.4m / Enterprise Value 10.5b)
FCF Margin = 79.37% (FCF TTM 431.4m / Revenue TTM 543.4m)
Net Margin = 65.40% (Net Income TTM 355.4m / Revenue TTM 543.4m)
Gross Margin = 77.91% ((Revenue TTM 543.4m - Cost of Revenue TTM 120.0m) / Revenue TTM)
Gross Margin QoQ = none% (prev 56.85%)
Tobins Q-Ratio = 1.76 (Enterprise Value 10.5b / Total Assets 5.93b)
Interest Expense / Debt = 4.20% (Interest Expense 50.6m / Debt 1.21b)
Taxrate = 2.41% (8.78m / 363.7m)
NOPAT = 404.3m (EBIT 414.3m * (1 - 2.41%))
Current Ratio = 1.20 (Total Current Assets 625.1m / Total Current Liabilities 520.9m)
Debt / Equity = 0.27 (Debt 1.21b / totalStockholderEquity, last quarter 4.49b)
Debt / EBITDA = 2.19 (Net Debt 1.16b / EBITDA 528.1m)
Debt / FCF = 2.68 (Net Debt 1.16b / FCF TTM 431.4m)
Total Stockholder Equity = 4.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.71% (Net Income 355.4m / Total Assets 5.93b)
RoE = 8.54% (Net Income TTM 355.4m / Total Stockholder Equity 4.16b)
RoCE = 8.19% (EBIT 414.3m / Capital Employed (Equity 4.16b + L.T.Debt 895.1m))
RoIC = 7.10% (NOPAT 404.3m / Invested Capital 5.69b)
WACC = 5.60% (E(9.30b)/V(10.5b) * Re(5.79%) + D(1.21b)/V(10.5b) * Rd(4.20%) * (1-Tc(0.02)))
Discount Rate = 5.79% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.06 | Cagr: 28.52%
[DCF] Terminal Value 77.97% ; FCFF base≈379.2m ; Y1≈434.7m ; Y5≈639.8m
[DCF] Fair Price = 35.86 (EV 9.63b - Net Debt 1.16b = Equity 8.47b / Shares 236.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.76 | EPS CAGR: 25.54% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.37 | Revenue CAGR: 45.01% | SUE: 0.21 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.43 | Chg30d=+1.76% | Revisions=+17% | Analysts=4
EPS current Year (2026-12-31): EPS=1.81 | Chg30d=+0.55% | Revisions=+40% | GrowthEPS=+33.8% | GrowthRev=+27.2%
EPS next Year (2027-12-31): EPS=1.77 | Chg30d=+1.87% | Revisions=+17% | GrowthEPS=-2.2% | GrowthRev=+28.4%
[Analyst] Revisions Ratio: +36% (up=6, down=2)